X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
hAd5 S+N is unique in targeting both the spike (S) and nucleocapsid (N) proteins of the SARS-CoV-2 virus. First COVID-19 vaccine trials designed to deliver both S and N SARS-CoV-2 viral proteins via multiple routes—subcutaneous, sublingual, and oral.
Lead Product(s): hAd5-S-Fusion+N-ETSD Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: hAd5 S+N
Highest Development Status: Phase IProduct Type: Vaccine
Recipient: ImmunityBio
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2021
Details:
NantKwest and ImmunityBio’s QUILT 88 Trial shows novel combination immunotherapy, which includes which include CytRx’s licensed drug aldoxorubicin, has more than doubled historic median survival rates in patients.
Lead Product(s): Aldoxorubicin HCl,PD-L1 t-haNK,Paclitaxel
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: CytRx Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 15, 2021
Details:
The combination of NantKwest’s Natural Killer (NK) cell platform and ImmunityBio’s immunotherapy fusion protein, immunomodulator, and adenovirus platforms have already resulted in complete responses in late stage, difficult to treat metastatic cancers.
Lead Product(s): N-803,BCG Vaccine
Therapeutic Area: Oncology Product Name: Anktiva
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Recipient: ImmunityBio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger December 21, 2020
Details:
The transaction is structured as a tax-free 100% stock-for-stock merger, with ImmunityBio to reverse merge with NantKwest. Following the closing of the transaction, the combined company will assume the ImmunityBio name and continue to be listed on the NASDAQ exchange.
Lead Product(s): Aldoxorubicin HCl,N-803,PD-L1 t-haNK
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: ImmunityBio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger December 21, 2020
Details:
Developed by ImmunityBio and manufactured by NantKwest, this second generation hAd5-vector vaccine is unique in targeting both spike and nucleocapsid SARS-CoV-2 proteins. Low dose cohort reports no serious adverse events, high dose cohort safety analysis ongoing.
Lead Product(s): hAd5-S-Fusion+N-ETSD Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: hAd5
Highest Development Status: Phase IProduct Type: Vaccine
Recipient: ImmunityBio
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2020
Details:
First patient has been dosed in the Phase 1 clinical trial of hAd5-COVID-19, a novel COVID-19 vaccine candidate that targets the inner nucleocapsid (N) and the outer spike (S) protein, engineered to activate both T cells and antibodies against the coronavirus (SARS-CoV-2).
Lead Product(s): hAd5-S-Fusion+N-ETSD Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: hAd5
Highest Development Status: Phase IProduct Type: Vaccine
Recipient: ImmunityBio
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2020
Details:
Third cohort added to independently evaluate the efficacy of NantKwest’s PD-L1 t-haNK natural killer cells plus ImmunityBio’s IL-15 superagonist AnktivaÔ (N-803) in third-line or greater therapy for patients with locally advanced or metastatic pancreatic cancer.
Lead Product(s): PD-L1 t-haNK,N-803,Aldoxorubicin HCl
Therapeutic Area: Oncology Product Name: PD-L1 t-haNK
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: ImmunityBio
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2020
Details:
Preliminary data from NantKwest collaborators suggests mesenchymal stem cell treatments may benefit COVID-19 patients with acute respiratory distress syndrome and cytokine storm.
Lead Product(s): BM-Allo.MSC
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2020
Details:
Open-label, randomized Phase 2 study will evaluate combination immunotherapy, including NantKwest’s PD-L1 tumor-targeted natural killer cells and ImmunityBio’s IL-15 superagonist N-803 with standard of care versus standard of care alone.
Lead Product(s): PD-L1 t-haNK,N-803,Aldoxorubicin HCl
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2020
Details:
Under this collaboration, NantKwest and ImmunityBio are combining their resources to design and develop therapeutics and vaccines for COVID-19.
Lead Product(s): HaNK
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: ImmunityBio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
